Angiodynamics: Pay

Angiodynamics paid its 5 named executives $11.4M in total in FY2025 (May). CEO James C. Clemmer was paid $5.5M of that.

Pay$100 in the stock at the end of FY20 → $100
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

James C. ClemmerPresident, CEO
FY2025 (May)
FY2024 (May)
FY2023 (May)
FY2022 (May)Not disclosed
FY2021 (May)Not disclosed
5 years
Stephen A. TrowbridgeEVP, CFO
FY2025 (May)
FY2024 (May)
FY2023 (May)
FY2022 (May)Not disclosed
FY2021 (May)Not disclosed
5 years
Laura PiccininiSVP & GM, Cardiovascular and International
FY2025 (May)
FY2024 (May)
FY2023 (May)
FY2022 (May)Not disclosed
4 years
Lawrence T. WeissSVP & Chief Legal Officer
FY2025 (May)
1 year
Warren NighanSVP & GM, Global Supply Chain, Quality and Regulatory Affairs
FY2025 (May)
FY2024 (May)
2 years

CEO pay against the pay peers

In FY2025 (May), the median CEO pay of the 5 peers with pay on file was $9.2M. The CEO of Angiodynamics was paid $5.5M, 40% below the median.

  1. 1GLAUKOS
  2. 2Alphatec Holdings
  3. 3AtriCure
  4. 4Axogen
  5. 5Staar Surgical
  6. 6Angiodynamics
  7. 7Accuray IncorporatedNot disclosed
  8. 8Artivian, Inc.Not disclosed
  9. 9Atrion CorporationNot disclosed
  10. 10Cutera, Inc.Not disclosed
  11. 11Inari Medical, Inc.Not disclosed
  12. 12Lemaitre VascularNot disclosed
  13. 13Nevro Corp.Not disclosed
  14. 14Orthofix MedicalNot disclosed
  15. 15Surmodics, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.